Safety, tolerability and pharmacokinetics of emodepside, a potential novel treatment for onchocerciasis (river blindness), in healthy male subjects
British Journal of Clinical Pharmacology2021Vol. 87(10), pp. 3949–3960
Citations Over TimeTop 18% of 2021 papers
Jean‐Yves Gillon, Jeremy Dennison, Frans van den Berg, Sophie Delhomme, Karen Dequatre Cheeseman, Claudia Peña Rossi, Nathalie Strub‐Wourgaft, Sabine Specht, Belén Pedrique, Frédéric Monnot, Susanne Skrabs, Maria‐Luisa Rodriguez, Heino Staß
Abstract
Overall, emodepside had acceptable safety and tolerability profiles, no major safety concerns, after single oral administration of 20 mg as LSF and after multiple oral administration over 10 days at 5 and 10 mg OD and at 10 mg twice daily. For further clinical trials, the development of a tablet formulation overcoming the limitations observed in the present study with the IR tablet formulation is considered.
Related Papers
- → Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine(1988)341 cited
- → Repeated oral administration modulates the pharmacokinetic behavior of the chemopreventive agent phenethyl isothiocyanate in rats(2009)37 cited
- → Enhanced Oral Bioavailability of DDI After Administration of 6-Cl-ddP, an Adenosine Deaminase-Activated Prodrug, to Chronically Catheterized Rats(1995)20 cited
- → Pharmacokinetics of a Micronized, Poorly Water-Soluble Drug, HO-221, in Experimental Animals.(1993)18 cited
- [The pharmacokinetics of rhein in 12 healthy volunteers after oral administration of rhubarb extract].(2005)